Imagion Biosystems (ASX:IBX) share price soars 13% on quarterly update

Here's what is driving the Imagion share price higher today.

The Imagion Biosystems Ltd (ASX: IBX) share price is taking off following the release of the company's quarterly report.

Over the third quarter of the calendar year 2022, the company moved forward with its MagSense Study and entered a new joint development agreement.

The market has reacted favourably to all the company has achieved. At the time of writing, the Imagion share price is 7.6 cents, which is 13.43% higher than its previous close.

Let's take a closer look at what the cancer imaging technology company has been up to over the 3 months ending 30 September.

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital

Image source: Getty Images

The quarter just been for Imagion

The Imagion share price is surging on news the company has enrolled multiple patients in its MagSense HER2 Breast Cancer Phase I Study.

The study is looking to find if the company's novel imaging agent, developed specifically for breast cancer patients who test positive for the Human Epidermal Growth Factor Receptor 2 (HER2), is safe for use.

The company signed one hospital on as a clinical site during the quarter, and another since its end. Four hospitals have now agreed to be involved in the study.

The company's chair and CEO, Bob Proulx commented:  

As we see how the end of lock downs affects cancer screening, we will have a better indication over [quarter 4] as to the likely cadence of recruitment going forward.

Further, the company has partnered with Global Cancer Technology to develop its partner's novel nanoscintillator technology. The technology aims to treat breast cancer and will utilise Imagion's nanoparticle expertise.

Under the terms of their agreement, Global Cancer Technology will pay Imagion for research and development services. Meanwhile, Imagion will gain a holding in the product.

Finally, Imagion has used its grant from the CSIRO to fund the first round of animal studies for its MagSense prostate cancer imaging agent. Results of the animal studies are currently being analysed.

The company spent $2.2 million over the course of the quarter.

It stated its costs will probably increase in the near future as its MagSense clinical study gets up and running. Its costs will also likely grow as its development pipeline advances.

The company ended the quarter with $12 million of cash in the bank. That's enough to fund another 5.5 quarters if its expenses remain the same.

Imagion share price snapshot

Today's gains included, the Imagion share price has fallen 45% since the start of 2021. However, it is 8.5% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »